ZACTIMA (an Anti-EGFR / Anti-VEGF Agent) Combined With Docetaxel Compared to Docetaxel in Non-small Cell Lung Cancer (ZODIAC)
A Phase III, Randomized, Double-Blinded, Multi-Center, Study to Assess the Efficacy of Docetaxel (TAXOTERE™) in Combination With ZD6474 (ZACTIMA™) Versus Docetaxel (TAXOTERE™) With Placebo in Subjects With Locally Advanced or Metastatic NSCLC
This large phase III clinical study is studying the effect of vandetanib (ZACTIMA) in treating non-small cell lung cancer (NSCLC). Vandetanib is a new type of agent that targets the blood supply to a cancer tumour (through it's anti-vascular endothelial growth factor receptor (VEGFR) properties) and the tumour cells themselves (through it's anti-endothelial growth factor receptor (EGFR) actions). This study will look at the effects of vandetanib in lung cancer patients who have had their cancer re-appear after treatment with standard chemotherapy.
This clinical study will test if the vandetanib anti-VEGF and anti-EGFR characteristics can deliver longer improved progression free survival and improved overall survival than docetaxel (Taxotere) alone.
All patients participating this clinical study will receive treatment with docetaxel, a commonly used treatment for recurrent non-small cell lung cancer.
In addition, some patients will also receive vandetanib (ZACTIMA), an anti-EGFR / anti-VEGF agent.
Recent clinical research shows that vascular endothelial growth factor receptor (VEGFR) inhibition, when used with standard chemotherapy, can lead to increased survival in advanced non-small cell lung cancer (NSCLC) patients.
Other research shows that epidermal growth factor receptor (EGFR) inhibitors, like erlotinib (Tarceva) can also increase overall non-small cell lung cancer survival by killing tumour cells and stopping them from dividing.
調査の概要
研究の種類
入学 (実際)
段階
- フェーズ 3
連絡先と場所
研究場所
-
-
California
-
Fullerton、California、アメリカ
- Research Site
-
Los Angeles、California、アメリカ
- Research Site
-
Northridge、California、アメリカ
- Research Site
-
-
Colorado
-
Colorado Springs、Colorado、アメリカ
- Research Site
-
-
Connecticut
-
Norwalk、Connecticut、アメリカ
- Research Site
-
-
Florida
-
Ocala、Florida、アメリカ
- Research Site
-
-
Georgia
-
Marietta、Georgia、アメリカ
- Research Site
-
-
Illinois
-
Joliet、Illinois、アメリカ
- Research Site
-
Park Ridge、Illinois、アメリカ
- Research Site
-
-
Kansas
-
Hutchinson、Kansas、アメリカ
- Research Site
-
-
Kentucky
-
Louisville、Kentucky、アメリカ
- Research Site
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ
- Research Site
-
-
Michigan
-
Ann Arbor、Michigan、アメリカ
- Research Site
-
-
Missouri
-
St. Louis、Missouri、アメリカ
- Research Site
-
-
Nevada
-
Henderson、Nevada、アメリカ
- Research Site
-
-
New York
-
Albany、New York、アメリカ
- Research Site
-
Armonk、New York、アメリカ
- Research Site
-
New York、New York、アメリカ
- Research Site
-
-
North Carolina
-
Durham、North Carolina、アメリカ
- Research Site
-
Hickory、North Carolina、アメリカ
- Research Site
-
-
Oregon
-
Portland、Oregon、アメリカ
- Research Site
-
-
Texas
-
Austin、Texas、アメリカ
- Research Site
-
Houston、Texas、アメリカ
- Research Site
-
-
Utah
-
Ogden、Utah、アメリカ
- Research Site
-
-
Virginia
-
Alexandria、Virginia、アメリカ
- Research Site
-
Salem、Virginia、アメリカ
- Research Site
-
-
Washington
-
Vancouver、Washington、アメリカ
- Research Site
-
-
-
-
-
Bahía Blanca、アルゼンチン
- Research Site
-
Capital Federal、アルゼンチン
- Research Site
-
Ciudad de Buenos Aires、アルゼンチン
- Research Site
-
Mendoza、アルゼンチン
- Research Site
-
Rosario、アルゼンチン
- Research Site
-
-
-
-
-
Ancona、イタリア
- Research Site
-
Avellino、イタリア
- Research Site
-
Bologna、イタリア
- Research Site
-
Genova、イタリア
- Research Site
-
Mantova、イタリア
- Research Site
-
Napoli、イタリア
- Research Site
-
Orbassano、イタリア
- Research Site
-
Parma、イタリア
- Research Site
-
Perugia、イタリア
- Research Site
-
Pisa、イタリア
- Research Site
-
Reggio Emilia、イタリア
- Research Site
-
-
-
-
-
Ahmedabad、インド
- Research Site
-
Chennai、インド
- Research Site
-
Hyderabad、インド
- Research Site
-
Kolkata、インド
- Research Site
-
New Delhi、インド
- Research Site
-
Pune、インド
- Research Site
-
Vellore、インド
- Research Site
-
-
-
-
-
Jakarta Timur、インドネシア
- Research Site
-
Yogyakarta、インドネシア
- Research Site
-
-
-
-
-
Amsterdam、オランダ
- Research Site
-
Den Bosch、オランダ
- Research Site
-
Groningen、オランダ
- Research Site
-
Maastricht、オランダ
- Research Site
-
-
-
-
-
Graz、オーストリア
- Research Site
-
Grimmenstein、オーストリア
- Research Site
-
Innsbruck、オーストリア
- Research Site
-
Linz、オーストリア
- Research Site
-
Wels、オーストリア
- Research Site
-
Wien、オーストリア
- Research Site
-
-
-
-
-
Quebec、カナダ
- Research Site
-
-
Alberta
-
Edmonton、Alberta、カナダ
- Research Site
-
-
New Brunswick
-
Moncton、New Brunswick、カナダ
- Research Site
-
-
Nova Scotia
-
Halifax、Nova Scotia、カナダ
- Research Site
-
-
Ontario
-
Kitchener、Ontario、カナダ
- Research Site
-
London、Ontario、カナダ
- Research Site
-
Toronto、Ontario、カナダ
- Research Site
-
-
Quebec
-
Laval、Quebec、カナダ
- Research Site
-
-
-
-
-
Athens、ギリシャ
- Research Site
-
Heraklion、ギリシャ
- Research Site
-
-
-
-
-
Singapore、シンガポール
- Research Site
-
-
-
-
-
A Coruña、スペイン
- Research Site
-
Alicante、スペイン
- Research Site
-
Madrid、スペイン
- Research Site
-
Málaga、スペイン
- Research Site
-
Zaragoza、スペイン
- Research Site
-
-
-
-
-
Chiang Mai、タイ
- Research Site
-
-
-
-
-
Herlev、デンマーク
- Research Site
-
København Ø、デンマーク
- Research Site
-
Odense、デンマーク
- Research Site
-
Roskilde、デンマーク
- Research Site
-
Vejle、デンマーク
- Research Site
-
-
-
-
-
Bad Berka、ドイツ
- Research Site
-
Berlin、ドイツ
- Research Site
-
Essen、ドイツ
- Research Site
-
Großhansdorf、ドイツ
- Research Site
-
Halle、ドイツ
- Research Site
-
Hamburg、ドイツ
- Research Site
-
Heidelberg、ドイツ
- Research Site
-
Köln、ドイツ
- Research Site
-
Oldenburg、ドイツ
- Research Site
-
Ulm、ドイツ
- Research Site
-
Wiesbaden、ドイツ
- Research Site
-
-
-
-
-
Bordeaux Cedex、フランス
- Research Site
-
Boulogne Billancourt、フランス
- Research Site
-
Caen Cedex、フランス
- Research Site
-
Dijon、フランス
- Research Site
-
Nancy、フランス
- Research Site
-
Paris、フランス
- Research Site
-
Pierre Benite Cedex、フランス
- Research Site
-
Saint Herblain、フランス
- Research Site
-
-
-
-
-
Fortaleza、ブラジル
- Research Site
-
Goiânia、ブラジル
- Research Site
-
Porto Alegre、ブラジル
- Research Site
-
Rio de Janeiro、ブラジル
- Research Site
-
Sao Paulo、ブラジル
- Research Site
-
-
-
-
-
Hanoi city、ベトナム
- Research Site
-
Ho Chi Minh city、ベトナム
- Research Site
-
-
-
-
-
Brussels (Jette)、ベルギー
- Research Site
-
Brussels (Woluwé-St-Lambert)、ベルギー
- Research Site
-
Edegem、ベルギー
- Research Site
-
Genk、ベルギー
- Research Site
-
Liege、ベルギー
- Research Site
-
-
-
-
-
Coimbra、ポルトガル
- Research Site
-
Funchal、ポルトガル
- Research Site
-
Lisboa、ポルトガル
- Research Site
-
Porto、ポルトガル
- Research Site
-
Vila Nova de Gaia、ポルトガル
- Research Site
-
-
-
-
-
Kubang Kerian、マレーシア
- Research Site
-
Nilai、マレーシア
- Research Site
-
Penang、マレーシア
- Research Site
-
-
-
-
-
Durango、メキシコ
- Research Site
-
Morelia、メキシコ
- Research Site
-
Toluca、メキシコ
- Research Site
-
-
-
-
-
Ankara、七面鳥
- Research Site
-
Istanbul、七面鳥
- Research Site
-
Izmir、七面鳥
- Research Site
-
-
-
-
-
Beijing、中国
- Research Site
-
Chongqing、中国
- Research Site
-
Guangzhou、中国
- Research Site
-
Nanjing、中国
- Research Site
-
Shanghai、中国
- Research Site
-
Wuhan、中国
- Research Site
-
-
-
-
-
Seoul、大韓民国
- Research Site
-
-
-
-
-
Akashi-shi、日本
- Research Site
-
Fukuoka、日本
- Research Site
-
Fukuoka-shi、日本
- Research Site
-
Isehara-shi、日本
- Research Site
-
Kobe-shi、日本
- Research Site
-
Koto-ku、日本
- Research Site
-
Kumamoto-shi、日本
- Research Site
-
Matsuyama-shi、日本
- Research Site
-
Nagoya-shi、日本
- Research Site
-
Okayama-shi、日本
- Research Site
-
Okazaki-shi、日本
- Research Site
-
Osaka-shi、日本
- Research Site
-
Osakasayama-shi、日本
- Research Site
-
Sakai-shi、日本
- Research Site
-
Sapporo-shi、日本
- Research Site
-
Shinjuku-ku、日本
- Research Site
-
Sunto-gun、日本
- Research Site
-
Toyonaka、日本
- Research Site
-
Ube-shi、日本
- Research Site
-
Utsunomiya-shi、日本
- Research Site
-
Yokohama-shi、日本
- Research Site
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
Lung cancer patients who answer true to the following statements are eligible to join this clinical study.
- I have a confirmed diagnosis of locally advanced or metastatic non small cell lung cancer (Stage IIIb - IV)
- I have had 1st line anti-cancer therapy. Previous treatment with Avastin (bevacizumab) in first line NSCLC is allowed.
Exclusion Criteria:
Lung cancer patients who answer true to the following are NOT eligible to join this clinical study.
- I do not have non small cell lung cancer (NSCLC)
- I have received treatment with docetaxel (Taxotere). Prior treatment with paclitaxel is acceptable.
- I have received 2nd line anti-cancer therapy (For example, patients with previous 2nd line non small cell lung cancer (NSCLC) treatment with Tarceva (erlotinib, OSI-744), Alimta (pemetrexed) are not eligible)
- I have been treated with VEGFR-tyrosine kinase inhibitors (TKIs) (sunitinib, sorafenib, other VEGF TKIs). Previous treatment with Avastin (bevacizumab) in 1st line non small cell lung cancer is permitted.
- I have a history of uncontrolled irregular heartbeat
- I have a history of high blood pressure which has not been controlled with medication If you are unsure of the meaning of the inclusion and exclusion criteria above, please contact the call center number for help.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:4倍
武器と介入
参加者グループ / アーム |
介入・治療 |
---|---|
実験的:2
バンデタニブ + ドセタキセル
|
infusion
他の名前:
oral
他の名前:
|
アクティブコンパレータ:1
Docetaxel monotherapy
|
infusion
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Progression-Free Survival (PFS) in the Overall Population
時間枠:RECIST tumour assessments carried out every 6 weeks from randomisation until the date of first documented objective disease progression or date of death from any cause, whichever came first assessed up to 24 months
|
Median time (in weeks) from randomisation until objective disease progression or death (by any cause in the absence of objective progression) provided death is within 3 months from the last evaluable RECIST assessment.
Progression was derived according to RECIST 1.0 and is defined as an increase of at least 20% in the total tumour size of measurable lesions over the nadir measurement, unequivocal progression in the non-target lesions or the appearance of one or more new lesions.
|
RECIST tumour assessments carried out every 6 weeks from randomisation until the date of first documented objective disease progression or date of death from any cause, whichever came first assessed up to 24 months
|
Progression-Free Survival (PFS) in the Female Population
時間枠:RECIST tumour assessments carried out every 6 weeks from randomisation until the date of first documented objective disease progression or date of death from any cause, whichever came first assessed up to 24 months
|
Median time (in weeks) from randomisation until objective disease progression or death (by any cause in the absence of objective progression) provided death is within 3 months from the last evaluable RECIST assessment.
Progression was derived according to RECIST 1.0 and is defined as an increase of at least 20% in the total tumour size of measurable lesions over the nadir measurement, unequivocal progression in the non-target lesions or the appearance of one or more new lesions.
|
RECIST tumour assessments carried out every 6 weeks from randomisation until the date of first documented objective disease progression or date of death from any cause, whichever came first assessed up to 24 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Overall Survival (OS) in the Overall Population
時間枠:Time to death in months
|
Overall survival is defined as the time from date of randomization until death.
Any patient not known to have died at the time of analysis will be censored based on the last recorded date on which the patient was known to be alive (ie their status must be known at the censored date and should not be lost to follow up or unknown).
|
Time to death in months
|
Overall Survival (OS) in the Female Population
時間枠:Time to death in months
|
Overall survival is defined as the time from date of randomization until death.
Any patient not known to have died at the time of analysis will be censored based on the last recorded date on which the patient was known to be alive (ie their status must be known at the censored date and should not be lost to follow up or unknown).
|
Time to death in months
|
Objective Response Rate (ORR)
時間枠:Each patient was assessed for objective response from the sequence of RECIST scan data up to data cut off. RECIST tumour assessments carried out every 6 weeks from randomisation until objective progression
|
The ORR is the number of patients that are responders ie those patients with a confirmed best objective response of complete response (CR) or partial response (PR) as determined according to RECIST 1.0.
CR is defined as the disappearance of all target lesions with no evidence of tumour elsewhere and PR is defined as at least a 30% reduction in the total tumour size of measurable lesions with no new lesions and no progression in the non-target lesions.
|
Each patient was assessed for objective response from the sequence of RECIST scan data up to data cut off. RECIST tumour assessments carried out every 6 weeks from randomisation until objective progression
|
Disease Control Rate (DCR)
時間枠:RECIST tumour assessments carried out every 6 weeks from randomisation until objective progression
|
Disease control rate is defined as the number of patients who achieved disease control at least 6 weeks following randomisation.
Disease control at 6 weeks is defined as a best objective response of complete response (CR), partial response (PR) or stable disease (SD) >= 6 weeks as determined according to RECIST 1.0.
CR is defined as the disappearance of all target lesions with no evidence of tumour elsewhere, PR is defined as at least a 30% reduction in the total tumour size of measurable lesions with no new lesions and no progression in the non-target lesions and SD >= 6 is assigned to patients who have not responded and have no evidence of progression at least 6 weeks after randomisation.
|
RECIST tumour assessments carried out every 6 weeks from randomisation until objective progression
|
Duration of Response (DoR)
時間枠:RECIST tumour assessments carried out every 6 weeks from randomisation until objective progression
|
Response is defined as a confirmed best objective response of CR or PR.
Duration of response is defined as time from the date of first documented response until date of documented progression or death in the absence of disease progression (provided death is within 3 months of last RECIST assessment)
|
RECIST tumour assessments carried out every 6 weeks from randomisation until objective progression
|
Time to Deterioration of Disease-related Symptoms (TDS) by Functional Assessment of Cancer Therapy - Lung (FACT-L) Lung Cancer Subscale (LCS).
時間枠:FACT-L questionnaires are to be administered every 3 weeks after randomisation
|
The lung cancer subscale (LCS) consists of 7 items of the FACT-L (3 items relating to breathing/dyspnea, and 1 item each relating to cough, weight loss, appetite, and cognition). The LCS total score is the sum of the scores from the 7 items. Time to deterioration is defined as the interval from the date of randomization to the first assessment of worsened without an improvement in the next 21 days. A patient will be defined as having a deterioration in symptoms if they have a single visit assessment of 'worsened' with no visit assessment of 'improved' within the next 21 days. |
FACT-L questionnaires are to be administered every 3 weeks after randomisation
|
Time to Deterioration of Disease-related Symptoms (TDS) by FACT-L Pulmonary Symptom Index (PSI)
時間枠:FACT-L questionnaires are to be administered every 3 weeks after randomisation
|
The pulmonary symptom index (PSI) consists of 4 items of the LCS relating to pulmonary symptoms (i.e. 3 items relating to breathing/dyspnea, and 1 item relating to cough). The PSI score is the sum of the scores from the 4 items. Time to deterioration is defined as the interval from the date of randomization to the first assessment of worsened without an improvement in the next 21 days. A patient will be defined as having a deterioration in symptoms if they have a single visit assessment of 'worsened' with no visit assessment of 'improved' within the next 21 days. |
FACT-L questionnaires are to be administered every 3 weeks after randomisation
|
協力者と研究者
捜査官
- スタディディレクター:Contact-US@sanofi.com、Sanofi
出版物と役立つリンク
一般刊行物
- Platt A, Morten J, Ji Q, Elvin P, Womack C, Su X, Donald E, Gray N, Read J, Bigley G, Blockley L, Cresswell C, Dale A, Davies A, Zhang T, Fan S, Fu H, Gladwin A, Harrod G, Stevens J, Williams V, Ye Q, Zheng L, de Boer R, Herbst RS, Lee JS, Vasselli J. A retrospective analysis of RET translocation, gene copy number gain and expression in NSCLC patients treated with vandetanib in four randomized Phase III studies. BMC Cancer. 2015 Mar 23;15:171. doi: 10.1186/s12885-015-1146-8.
- Lombard A, Mistry H, Aarons L, Ogungbenro K. Dose individualisation in oncology using chemotherapy-induced neutropenia: Example of docetaxel in non-small cell lung cancer patients. Br J Clin Pharmacol. 2021 Apr;87(4):2053-2063. doi: 10.1111/bcp.14614. Epub 2020 Dec 19.
- Heymach JV, Lockwood SJ, Herbst RS, Johnson BE, Ryan AJ. EGFR biomarkers predict benefit from vandetanib in combination with docetaxel in a randomized phase III study of second-line treatment of patients with advanced non-small cell lung cancer. Ann Oncol. 2014 Oct;25(10):1941-1948. doi: 10.1093/annonc/mdu269. Epub 2014 Jul 23.
- Herbst RS, Sun Y, Eberhardt WE, Germonpre P, Saijo N, Zhou C, Wang J, Li L, Kabbinavar F, Ichinose Y, Qin S, Zhang L, Biesma B, Heymach JV, Langmuir P, Kennedy SJ, Tada H, Johnson BE. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol. 2010 Jul;11(7):619-26. doi: 10.1016/S1470-2045(10)70132-7.
便利なリンク
研究記録日
主要日程の研究
研究開始
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (見積もり)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
肺癌の臨床試験
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI); Highlight Therapeutics積極的、募集していない平滑筋肉腫 | 悪性末梢神経鞘腫瘍 | 滑膜肉腫 | 未分化多形肉腫 | 骨の未分化高悪性度多形肉腫 | 粘液線維肉腫 | II期の体幹および四肢の軟部肉腫 AJCC v8 | III期の体幹および四肢の軟部肉腫 AJCC v8 | IIIA 期の体幹および四肢の軟部肉腫 AJCC v8 | IIIB 期の体幹および四肢の軟部肉腫 AJCC v8 | 切除可能な軟部肉腫 | 多形性横紋筋肉腫 | 切除可能な脱分化型脂肪肉腫 | 切除可能な未分化多形肉腫 | 軟部組織線維肉腫 | 紡錘細胞肉腫 | ステージ I 後腹膜肉腫 AJCC (American Joint Committee on Cancer) v8 | 体幹および四肢の I 期軟部肉腫 AJCC v8 | ステージ... およびその他の条件アメリカ